Associated Press: Omeros Corporation — Award Winning Drug OMS824 Being Tested to Treat Huntington’s & Schizophrenia

Omeros Corporation (OMER) will soon begin two mid stage clinical trials on its drug OMS824 which has greatly increased its stock prices. The company is testing its drug as a treatment for Huntington’s disease toward the end of 2013 as well as trials involved the treatment of Schizophrenia. The FDA has also awarded OMS824 orphan drug status as a treatment for Huntington’s. These two neurological disorders have been diagnosed in numerous Americas. The positive outlook thus far on this drug looks promising.

View the full article here (http://finance.yahoo.com/news/omeros-prepares-two-studies-oms824-182145630.html).

 

The comments are closed.